Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy - PubMed (original) (raw)

. 1988 Nov 18;260(19):2864-71.

Affiliations

PMID: 3184351

Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy

R Klein et al. JAMA. 1988.

Abstract

The relationship between hyperglycemia, measured by glycosylated hemoglobin at the initial examination, and the four-year incidence and progression of diabetic retinopathy was examined in a population-based study in Wisconsin. Younger- (n = 891) and older-onset (n = 987) persons participating in baseline and follow-up examinations were included. Glycosylated hemoglobin was measured by microcolumn. Retinopathy was determined from stereoscopic fundus photographs. In the younger-onset group, comparing the highest with the lowest quartile of glycosylated hemoglobin, the relative risk for developing any diabetic retinopathy was 1.9; for proliferative retinopathy, 21.8; and for progression, 4.0. Among older-onset persons taking insulin, the corresponding relative risks were 1.9, 4.0, and 2.1. Among older-onset persons not taking insulin, relative risks were 4.0 for any retinopathy and 6.2 for progression. A positive relationship between incidence and progression of retinopathy and glycosylated hemoglobin remained after controlling for duration of diabetes, age, sex, and baseline retinopathy. These data suggest a strong and consistent relationship between hyperglycemia and incidence and progression of retinopathy.

PubMed Disclaimer

Cited by

Personalizing Physical Activity for Glucose Control Among Individuals With Type 2 Diabetes: Are We There Yet?
Zhang C, Yang J. Zhang C, et al. Diabetes Care. 2024 Feb 1;47(2):196-198. doi: 10.2337/dci23-0063. Diabetes Care. 2024. PMID: 38241495 Free PMC article. No abstract available.
A bioengineered artificial interstitium supports long-term islet xenograft survival in nonhuman primates without immunosuppression.
Oppler SH, Hocum Stone LL, Leishman DJ, Janecek JL, Moore MEG, Rangarajan P, Willenberg BJ, O'Brien TD, Modiano J, Pheil N, Dalton J, Dalton M, Ramachandran S, Graham ML. Oppler SH, et al. Sci Adv. 2024 Jan 5;10(1):eadi4919. doi: 10.1126/sciadv.adi4919. Epub 2024 Jan 5. Sci Adv. 2024. PMID: 38181083 Free PMC article.
Risk of diabetic retinopathy and retinal neurodegeneration in individuals with type 2 diabetes: Beichen Eye Study.
Yang Z, Liu Q, Wen D, Yu Z, Zheng C, Gao F, Chen C, Hu L, Shi Y, Zhu X, Liu J, Shao Y, Li X. Yang Z, et al. Front Endocrinol (Lausanne). 2023 May 3;14:1098638. doi: 10.3389/fendo.2023.1098638. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37206443 Free PMC article.
Blood pressure control for diabetic retinopathy.
Do DV, Han G, Abariga SA, Sleilati G, Vedula SS, Hawkins BS. Do DV, et al. Cochrane Database Syst Rev. 2023 Mar 28;3(3):CD006127. doi: 10.1002/14651858.CD006127.pub3. Cochrane Database Syst Rev. 2023. PMID: 36975019 Free PMC article. Review.
Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.
Martinez-Zapata MJ, Salvador I, Martí-Carvajal AJ, Pijoan JI, Cordero JA, Ponomarev D, Kernohan A, Solà I, Virgili G. Martinez-Zapata MJ, et al. Cochrane Database Syst Rev. 2023 Mar 20;3(3):CD008721. doi: 10.1002/14651858.CD008721.pub3. Cochrane Database Syst Rev. 2023. PMID: 36939655 Free PMC article. Review.

Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy - PubMed (original) (raw)